Holen Sie sich die Stockscreener-App
23.88
5.43%
1.23
Vorhandelsmarkt:
23.88
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
AnaptysBio, Inc. (NASDAQ:ANAB) Holdings Trimmed by Bank of America Corp DE - MarketBeat
Assenagon Asset Management S.A. Sells 89,273 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio Holds 2025 Annual Stockholders Meeting - TipRanks
FMR LLC Significantly Reduces Stake in AnaptysBio Inc - GuruFocus
Stocks With Rising Relative Price Strength: AnaptysBio - Investor's Business Daily
JPMorgan Sees AnaptysBio (ANAB) as Undervalued Due to Rosnilimab - GuruFocus
Shareholders May Be More Conservative With AnaptysBio, Inc.'s (NASDAQ:ANAB) CEO Compensation For Now - simplywall.st
New RA Drug Shown to Work, Be Safe - streetwisereports.com
AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster Potential (NASDAQ:ANAB) - Seeking Alpha
ANAB Schedules June 9 Conference Call with JPMorgan | ANAB Stock News - GuruFocus
Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Price Target at $42.38 - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Up 9.1%Should You Buy? - MarketBeat
AnaptysBio (NASDAQ:ANAB) Trading Down 4.5%Time to Sell? - MarketBeat
AnaptysBio (NASDAQ:ANAB) Upgraded by HC Wainwright to "Buy" Rating - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Gap UpHere's What Happened - MarketBeat
AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement (NASDAQ:ANAB) - Seeking Alpha
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Squarepoint Ops LLC - MarketBeat
TD Cowen reiterates Buy rating on AnaptysBio stock following updated trial data - Investing.com Canada
AnaptysBio (NASDAQ:ANAB) Upgraded to “Buy” at HC Wainwright - Defense World
AnaptysBio (ANAB) Shares Drop Amid Trial Data Missteps - GuruFocus
HC Wainwright & Co. Upgrades AnaptysBio (LSE:0HFQ) - Nasdaq
J&J hurts AnaptysBio with anti-inflammatory data (ANAB:NASDAQ) - Seeking Alpha
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point - Benzinga
AnaptysBio (ANAB) Reveals Promising Phase 2b Results in Rheumato - GuruFocus
Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May - Benzinga
AnaptysBio describes ‘JAK-like’ efficacy for PD-1 drug in rheumatoid arthritis - Endpoints News
H.C. Wainwright upgrades AnaptysBio stock on positive trial data By Investing.com - Investing.com Canada
Anaptys stock gains on arthritis drug data (ANAB:NASDAQ) - Seeking Alpha
AnaptysBio’s Rosnilimab Shows ‘Best-in-Disease’ Profile in Phase 2b RA Trial - Insider Monkey
Stifel analysts reiterate Buy rating for AnaptysBio stock after RA study - Investing.com UK
HC Wainwright & Co. Upgrades AnaptysBio (ANAB) - Nasdaq
AnaptysBio (ANAB) Stock Upgraded by HC Wainwright & Co. with New - GuruFocus
AnaptysBio (ANAB) Stock Upgraded by HC Wainwright & Co. with New Target Price | ANAB Stock News - GuruFocus
HC Wainwright Upgrades AnaptysBio to Buy From Neutral, $38 Price Target - marketscreener.com
Stifel Reiterates Buy Rating on AnaptysBio (ANAB) - StreetInsider
AnaptysBio (ANAB) Gets Boost from Positive Phase 2 Trial Data | ANAB Stock News - GuruFocus
AnaptysBio reports promising Phase 2b trial results for RA drug By Investing.com - Investing.com India
AnaptysBio Stock Jumps On Promising Rheumatoid Arthritis Drug Readout; Retail Traders Brace For Potential Offering - Investing.com India
Transcript : AnaptysBio, Inc.Special Call - marketscreener.com
AnaptysBio Reports Positive Phase 2b Trial Results - TipRanks
AnaptysBio Reports Durable Responses, Favorable Safety for Rosnilimab in Arthritis Trial - marketscreener.com
AnaptysBio (ANAB) Reports Promising Results for Rosnilimab in Rheumatoid Arthritis | ANAB Stock News - GuruFocus
Anaptys Announces Positive Rosnilimab Data Updated Through Six M - GuruFocus
AnaptysBio reports promising Phase 2b trial results for RA drug - Investing.com Australia
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA - marketscreener.com
New Rheumatoid Arthritis Drug Achieves JAK-Like Efficacy with Better Safety Profile in Phase 2b Trial - Stock Titan
Millennium Management LLC Sells 185,049 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):